(0.34%) 5 117.06 points
(0.33%) 38 365 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.56%) $2.03
(0.33%) $2 354.90
(0.47%) $27.67
(4.05%) $959.45
(-0.25%) $0.932
(-0.42%) $10.98
(-0.58%) $0.796
(1.69%) $93.43
@ $6.23
発行日: 15 2月 2024 @ 05:20
リターン: -53.77%
前回のシグナル: 2月 15 - 00:48
前回のシグナル:
リターン: -7.02 %
Live Chart Being Loaded With Signals
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine...
Stats | |
---|---|
本日の出来高 | 63 809.00 |
平均出来高 | 283 248 |
時価総額 | 15.88M |
EPS | $0 ( 2024-02-15 ) |
次の収益日 | ( $-2.20 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.150 |
ATR14 | $0.0200 (0.69%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-12 | Cr Group L.p. | Buy | 1 647 315 | Common Stock |
2024-04-12 | Cr Group L.p. | Buy | 390 142 | Common Stock |
2024-04-12 | Cr Group L.p. | Buy | 682 036 | Common Stock |
2024-04-12 | Cr Group L.p. | Buy | 424 716 | Common Stock |
2024-04-12 | Cr Group L.p. | Buy | 136 409 | Common Stock |
INSIDER POWER |
---|
3.77 |
Last 99 transactions |
Buy: 52 592 861 | Sell: 43 240 632 |
ボリューム 相関
T2 Biosystems Inc 相関
10 最も負の相関 | |
---|---|
OFLX | -0.906 |
BLPH | -0.906 |
BCYP | -0.867 |
MNDY | -0.863 |
BNIXU | -0.857 |
SVFC | -0.857 |
INTA | -0.856 |
ASLN | -0.854 |
MKGI | -0.851 |
AZRX | -0.85 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
T2 Biosystems Inc 相関 - 通貨/商品
T2 Biosystems Inc 財務諸表
Annual | 2023 |
収益: | $7.19M |
総利益: | $-8.83M (-122.74 %) |
EPS: | $-19.19 |
FY | 2023 |
収益: | $7.19M |
総利益: | $-8.83M (-122.74 %) |
EPS: | $-19.19 |
FY | 2022 |
収益: | $22.31M |
総利益: | $1.17M (5.23 %) |
EPS: | $-1 242.48 |
FY | 2021 |
収益: | $28.06M |
総利益: | $7.36M (26.21 %) |
EPS: | $-20.29 |
Financial Reports:
No articles found.
T2 Biosystems Inc
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。